Zydus Lifesciences Limited has recently informed exchanges that the company received final United States Food and Drug Administration (USFDA) approval to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg.
Paliperidone extended-release tablets are recommended for the acute and maintenance treatment of schizophrenia, the acute treatment of schizoaffective disorder as monotherapy and the acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants.
Paliperidone extended-release tablets will be manufactured in the Group’s Ahmedabad SEZ manufacturing facility.
